Literature DB >> 32882637

Cross protection by inactivated recombinant influenza viruses containing chimeric hemagglutinin conjugates with a conserved neuraminidase or M2 ectodomain epitope.

Ki-Hye Kim1, Yu-Jin Jung1, Youri Lee1, Bo Ryoung Park1, Judy Oh1, Yu-Na Lee2, Min-Chul Kim3, Subbiah Jeeva1, Sang-Moo Kang4.   

Abstract

Influenza virus neuraminidase (NA) contains a universally conserved epitope (NAe, NA222-230). However, no studies have reported vaccines targeting this NA conserved epitope and inducing antibodies recognizing NAe. The extracellular domain of M2 (M2e) is considered as an attractive target for a universal influenza vaccine. We generated recombinant influenza H1N1 viruses expressing conserved epitopes in hemagglutinin (HA) molecules: NAe (NAe-HA) or M2e (M2e-HA) within the HA head domain. Inactivated recombinant NAe-HA and M2e-HA viruses were more effective in inducing IgG antibodies specific for an inserted conserved epitope than live recombinant virus. Recombinant inactivated M2e-HA virus vaccination induced cross protection against H3N2 virus with less weight loss compared to NAe-HA and was more effective in inducing humoral and cellular M2e immune responses. This study provides insight into developing recombinant influenza virus vaccines compatible with current platforms to induce antibody responses to conserved poorly immunogenic epitopes.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cross protection; Heterosubtypic immunity; M2 extracellular domain epitope; Neuraminidase epitope; Recombinant chimeric influenza virus

Mesh：

Substances：

Year:  2020        PMID： 32882637      PMCID： PMC7554235          DOI： 10.1016/j.virol.2020.08.003

Source DB:  PubMed          Journal:  Virology        ISSN： 0042-6822            Impact factor:   3.616


  50 in total

1.  H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge.

Authors:  Florian Krammer; Irina Margine; Rong Hai; Alexander Flood; Ariana Hirsh; Vadim Tsvetnitsky; Dexiang Chen; Peter Palese
Journal:  J Virol       Date:  2013-12-04       Impact factor: 5.103

2.  Association of serum anti-neuraminidase antibody with resistance to influenza in man.

Authors:  B R Murphy; J A Kasel; R M Chanock
Journal:  N Engl J Med       Date:  1972-06-22       Impact factor: 91.245

3.  Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults.

Authors:  Daniel F Hoft; Kathleen R Lottenbach; Azra Blazevic; Aldin Turan; Tamara P Blevins; Thomas P Pacatte; Yinyi Yu; Michelle C Mitchell; Stella G Hoft; Robert B Belshe
Journal:  Clin Vaccine Immunol       Date:  2017-01-05

4.  Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

Authors:  Andrea Jegerlehner; Nicole Schmitz; Tazio Storni; Martin F Bachmann
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

5.  Heterosubtypic immunity to lethal influenza A virus infection is associated with virus-specific CD8(+) cytotoxic T lymphocyte responses induced in mucosa-associated tissues.

Authors:  H H Nguyen; Z Moldoveanu; M J Novak; F W van Ginkel; E Ban; H Kiyono; J R McGhee; J Mestecky
Journal:  Virology       Date:  1999-02-01       Impact factor: 3.616

6.  Impact of erythrocyte species on assays for influenza serology.

Authors:  C M Trombetta; C Ulivieri; R J Cox; E J Remarque; C Centi; D Perini; G Piccini; S Rossi; S Marchi; E Montomoli
Journal:  J Prev Med Hyg       Date:  2018-03-30

7.  Cross-Protective Efficacy of Influenza Virus M2e Containing Virus-Like Particles Is Superior to Hemagglutinin Vaccines and Variable Depending on the Genetic Backgrounds of Mice.

Authors:  Yu-Jin Kim; Young-Tae Lee; Min-Chul Kim; Yu-Na Lee; Ki-Hye Kim; Eun-Ju Ko; Jae-Min Song; Sang-Moo Kang
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

8.  Sequential Immunization With Live-Attenuated Chimeric Hemagglutinin-Based Vaccines Confers Heterosubtypic Immunity Against Influenza A Viruses in a Preclinical Ferret Model.

Authors:  Wen-Chun Liu; Raffael Nachbagauer; Daniel Stadlbauer; Alicia Solórzano; Francesco Berlanda-Scorza; Adolfo García-Sastre; Peter Palese; Florian Krammer; Randy A Albrecht
Journal:  Front Immunol       Date:  2019-04-10       Impact factor: 7.561

9.  Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.

Authors:  David I Bernstein; Jeffrey Guptill; Abdollah Naficy; Raffael Nachbagauer; Francesco Berlanda-Scorza; Jodi Feser; Patrick C Wilson; Alicia Solórzano; Marie Van der Wielen; Emmanuel B Walter; Randy A Albrecht; Kristen N Buschle; Yao-Qing Chen; Carine Claeys; Michelle Dickey; Haley L Dugan; Megan E Ermler; Debra Freeman; Min Gao; Christopher Gast; Jenna J Guthmiller; Rong Hai; Carole Henry; Linda Yu-Ling Lan; Monica McNeal; Anna-Karin E Palm; Dustin G Shaw; Christopher T Stamper; Weina Sun; Victoria Sutton; Micah E Tepora; Rahnuma Wahid; Heather Wenzel; Teddy John Wohlbold; Bruce L Innis; Adolfo García-Sastre; Peter Palese; Florian Krammer
Journal:  Lancet Infect Dis       Date:  2019-10-17       Impact factor: 71.421

10.  Evaluation of Antihemagglutinin and Antineuraminidase Antibodies as Correlates of Protection in an Influenza A/H1N1 Virus Healthy Human Challenge Model.

Authors:  Matthew J Memoli; Pamela A Shaw; Alison Han; Lindsay Czajkowski; Susan Reed; Rani Athota; Tyler Bristol; Sarah Fargis; Kyle Risos; John H Powers; Richard T Davey; Jeffery K Taubenberger
Journal:  mBio       Date:  2016-04-19       Impact factor: 7.867
View more
  4 in total

1.  Enhanced cross protection by hetero prime-boost vaccination with recombinant influenza viruses containing chimeric hemagglutinin-M2e epitopes.

Authors:  Bo Ryoung Park; Jeeva Subbiah; Ki-Hye Kim; Young-Man Kwon; Judy Oh; Min-Chul Kim; Chong-Hyun Shin; Baik Lin Seong; Sang-Moo Kang
Journal:  Virology       Date:  2021-12-10       Impact factor: 3.616

2.  Physical radiofrequency adjuvant enhances immune responses to influenza H5N1 vaccination.

Authors:  Zhuofan Li; Ki-Hye Kim; Noopur Bhatnagar; Bo Ryoung Park; Subbiah Jeeva; Yu-Jin Jung; Jannatul Raha; Sang-Moo Kang; Xinyuan Chen
Journal:  FASEB J       Date:  2022-03       Impact factor: 5.191

3.  Broad cross protection by recombinant live attenuated influenza H3N2 seasonal virus expressing conserved M2 extracellular domain in a chimeric hemagglutinin.

Authors:  Bo Ryoung Park; Ki-Hye Kim; Tatiana Kotomina; Min-Chul Kim; Young-Man Kwon; Subbiah Jeeva; Yu-Jin Jung; Noopur Bhatnagar; Irina Isakova-Sivak; Daria Mezhenskaya; Larisa Rudenko; Bao-Zhong Wang; Sang-Moo Kang
Journal:  Sci Rep       Date:  2021-02-18       Impact factor: 4.379

Review 4.  Influenza Neuraminidase Characteristics and Potential as a Vaccine Target.

Authors:  Sarah Creytens; Mirte N Pascha; Marlies Ballegeer; Xavier Saelens; Cornelis A M de Haan
Journal:  Front Immunol       Date:  2021-11-16       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.